KyungMann Kim - Concepedia

Author

KyungMann Kim

University of Wisconsin–Madison

Also Known As

KyungMann Kim

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

University of Wisconsin–Madison Dana-Farber Cancer Institute University of Wisconsin Carbone Cancer Center Michigan State University University of Minnesota

About

KyungMann Kim is an author at University of Wisconsin–Madison specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	473
2	Public Health	1	1	43
3	Cellular Therapies	1	1	173
4	Clinical Immunology	1	1	173
5	Epidemiology	1	1	43

KyungMann Kim

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Celecoxib for the Prevention of Sporadic Colorectal Adenomas Monica M. Bertagnolli, Craig Eagle, Ann G. Zauber, New England Journal of Medicine	2006	1K
Chemotherapy With or Without Radiotherapy in Limited-Stage Diffuse Aggressive Non-Hodgkin's Lymphoma: Eastern Cooperative Oncology Group Study 1484 Sandra J. Horning, Edie Weller, KyungMann Kim, Journal of Clinical Oncology	2004	352
Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy David Delgado, Jacquelyn A. Hank, Jill Kolesar, Cancer Research Clinical ImmunologyCell TherapyImmunodeficienciesImmunologyImmunoediting	2010	173
Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma Fariba Navid, Paul M. Sondel, Raymond Barfield, Journal of Clinical Oncology	2014	158
Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients David M. King, Mark R. Albertini, Heidi Schalch, Journal of Clinical Oncology	2004	145
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells Stephanie Markovina, Natalie S. Callander, Shelby L. O’Connor, Molecular Cancer	2010	117
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC) Michael R. Harrison, Noah M. Hahn, William Oh, Investigational New Drugs NanomedicineUrologyPolymer-drug ConjugateMedicineTherapeutic Nanomaterials	2010	109
Intratumoral hu14.18–IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention Richard K. Yang, Nicholas A. Kalogriopoulos, Alexander L. Rakhmilevich, The Journal of Immunology	2012	72
A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer Glenn Liu, David R. Gandara, Primo N. Lara, Clinical Cancer Research Molecular PharmacologyUrologyPhase Ii TrialGenitourinary CancerMedicine	2004	67
High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial Orly Vardeny, Jacob A. Udell, Jacob Joseph, American Heart Journal VaccinationCross-protectionPreventive MedicineHealth PolicyClinical Trials	2018	43

Page 1